Email this article 
Characteristics of tissue expression of extracellular matrix proteolytic enzymes and their inhibitors in patients with bladder cancer
- Authors: Shevchenko A.N.1, Kit O.I.1, Komarova E.F.1, Nikipelova E.A.1, Demidova A.A.1, Pakus D.I.2, Sergan V.A.3, Filatova E.V.1, Khomutenko I.A.1
-
Affiliations:
- Rostov Research Institute of Oncology, Ministry of Health of Russia
- Clinical and Diagnostics Center “Health
- AMEOS Seepark Hospital Geestland Clinic for Urology and Pediatric Urology
- Issue: Vol 13, No 2 (2017)
- Pages: 96-103
- Section: DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCER
- Published: 30.06.2017
- URL: https://oncourology.abvpress.ru/oncur/article/view/664
- DOI: https://doi.org/10.17650/1726-9776-2017-13-2-96-103
- ID: 664
Cite item
Abstract
Objectives. Levels and expression of matrix metalloproteases 2 (MMP-2), MMP-9, MMP-14 and tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-2 were studied by immunohistochemistry in tumor and surrounding tissues in 73 patients with superficial bladder cancer (BC) ТаN0M0 and Т1N0M0 depending on the disease characteristics.
Results. The study showed the initial increase in the number of tumor cells expressing MMP-2, MMP-9 and MMP-14 and their tissue inhibitors, compared to histologically unchanged tissues and tumor-adjacent tissues. The number of MMP-9 producing tumor cells was maximal. Tissue expression of TIMP-1 and TIMP-2 in tumor cells in superficial BC patients was higher than in unchanged tissues and in tumor-adjacent tissues. The ratio of MMP and TIMP expression differed, and the proteolytic potential of MMP was higher than that of TIMP.
Conclusion. The study demonstrated the influence of the primary bladder cancer stage (from Ta to T1), tumor differentiation grade (from G1 to G2) and prognosis of the disease course (from favorable to intermediate) on the enhancing expression of MMP-9 and TIMP-1 in tumor tissues in superficial BC.
About the authors
A. N. Shevchenko
Rostov Research Institute of Oncology, Ministry of Health of Russia
Email: alexshew@mail.ru
ORCID iD: 0000-0002-9468-134X
Шевченко Алексей Николаевич, доктор медицинских наук, профессор, заведующий отделением онкоурологии Russian Federation
O. I. Kit
Rostov Research Institute of Oncology, Ministry of Health of Russia
Email: onko-sekretar@mail.ru
Кит Олег Иванович, профессор, член-корреспондент РАН, Заслуженный врач Российской Федерации, генеральный директор Russian Federation
E. F. Komarova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Email: katitako@gmail.com
Комарова Екатерина Федоровна, доктор биологических наук, профессор РАН, главный научный сотрудник Russian Federation
E. A. Nikipelova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Email: onko-sekretar@mail.ru
Никипелова Елена Алексеевна, доктор биологических наук, доцент, ученый секретарь
A. A. Demidova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Email: okt@rostgmu.ru
Демидова Александра Александровна, кандидат медицинских наук, доцент кафедры медицинской и биологической физики Russian Federation
D. I. Pakus
Clinical and Diagnostics Center “Health
Email: dmitry.pakus@rambler.ru
70/3 Dolomanovskiy Pereulok, Rostov-on-Don 344011 Russian Federation
V. A. Sergan
AMEOS Seepark Hospital Geestland Clinic for Urology and Pediatric Urology
Email: dr.sergan@mail.ru
Уролог Germany
E. V. Filatova
Rostov Research Institute of Oncology, Ministry of Health of Russia
Author for correspondence.
Email: lenafeel@mail.ru
ORCID iD: 0000-0002-7904-4414
63 14th Liniya St., Rostov-on-Don 344037 Russian Federation
I. A. Khomutenko
Rostov Research Institute of Oncology, Ministry of Health of Russia
Email: khomutenko@bk.ru
Хомутенко Ирина Анатольевна, кандидат медицинских наук, старший научный сотрудник, врач-онколог отделения онкоурологии Russian Federation
References
Supplementary files
